Revvity (NYSE:RVTY) Sets New 12-Month High – Time to Buy?

Shares of Revvity Inc. (NYSE:RVTY) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $134.37 and last traded at $135.1170, with a volume of 117173 shares. The stock had previously closed at $128.49.

Wall Street Analysts Forecast Growth

RVTY has been the subject of several research analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Sanford C. Bernstein initiated coverage on Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price on the stock. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Finally, UBS Group started coverage on shares of Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $116.57.

Revvity Stock Up 6.1%

The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $15.21 billion, a P/E ratio of 65.12, a PEG ratio of 2.26 and a beta of 1.09. The company has a fifty day moving average price of $118.03 and a 200-day moving average price of $103.47.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts forecast that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio is 13.33%.

Institutional Investors Weigh In On Revvity

Large investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its position in Revvity by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company’s stock valued at $41,048,000 after purchasing an additional 20,278 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Revvity in the 2nd quarter worth about $171,000. Nykredit A S bought a new stake in shares of Revvity in the 2nd quarter worth about $358,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Revvity during the 2nd quarter valued at about $823,000. Finally, California State Teachers Retirement System raised its position in shares of Revvity by 10,607.8% during the 2nd quarter. California State Teachers Retirement System now owns 14,328,063 shares of the company’s stock valued at $1,594,140,000 after buying an additional 14,194,254 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.